Smoflipid

Risk of parenteral nutrition-associated liver disease (PNALD)(eg, cholestasis or hepatic steatosis), other hepatobiliary disorders (eg, cholecystitis and cholelithiasis). Risk of deaths in preterm and small-for-gestational-age neonates; monitor for signs/symptoms of pleural or pericardial effusion. Correct severe fluid and electrolyte disorders prior to initiation. Increased risk of hypertriglyceridemia esp. in those with inherited lipid disorders, obesity, diabetes mellitus, or metabolic syndromes. Measure serum triglycerides at baseline and during therapy; if serum triglyceride >400mg/dL, discontinue and monitor levels. Assess high-risk patients for overall energy intake to minimize risk of new or worsening of hypertriglyceridemia. Discontinue if signs/symptoms of fat overload syndrome or hypersensitivity reactions occur; treat appropriately. Monitor for signs/symptoms of infection, essential fatty acid deficiency (EFAD). Severely undernourished: avoid overfeeding. Monitor fluids, electrolytes, blood glucose, liver (consider discontinuation or dose reduction if abnormal LFTs occur) and kidney function, CBCs, platelets, coagulation parameters throughout treatment. Hepatic impairment. Pregnancy. Nursing mothers.